SCHEMBL24377947

SCHEMBL24377947

O=C(Nc1ccccc1)C1CN(C(=O)CCl)c2ccccc2O1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
YAP1 P46937 1/20 0.49
TEAD4 Q15561 1/20 0.49
POLB P06746 1/20 0.47
SIRT1 Q96EB6 3/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45
RCE1 Q9Y256 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24377946 0.87 ALDH1A1 (0.50) YAP1TEAD4POLBNPC1RAB9A
SCHEMBL24378149 0.85 KMT2A (0.49) POLBSIRT1NPC1RAB9AKMT2A
SCHEMBL29516475 0.85 KMT2A (0.49) POLBSIRT1NPC1RAB9AKMT2A
SCHEMBL24378124 0.84 SIRT1 (0.52) POLBSIRT1NPC1RAB9AL3MBTL1
SCHEMBL29516196 0.84 SIRT1 (0.52) POLBSIRT1NPC1RAB9AL3MBTL1
SCHEMBL24377992 0.83 CYP1A2 (0.51) POLBSIRT1NPC1RAB9AKMT2A
SCHEMBL24378125 0.82 SIRT1 (0.65) SIRT1
SCHEMBL26938829 0.82 SIRT1 (0.65) SIRT1
SCHEMBL24378118 0.82 SIRT1 (0.65) SIRT1
SCHEMBL26939715 0.81 SIRT1 (0.47) POLBSIRT1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER CKMT1A; CKMT1B, PHKG1, PCK1 YAP1 4303/4885TEAD4 4532/4885POLB 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.